- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04804176
Study on the Mode and Mechanism of Ultra-low Frequency rTMS for Sleep Disorders in Patients With Parkinson's Disease
20. marts 2021 opdateret af: Lili Cao, Qianfoshan Hospital
Study on the Mode and Mechanism of Ultra-low Frequency Repetitive Transcranial Magnetic Stimulation for Sleep Disorders in Patients With Parkinson's Disease
The study by giving a sleep disorder Parkinson's disease patients with different patterns of ultra-low frequency transcranial magnetic stimulation or sham stimulation, scale for assessment of the patients were observed, hematology and imaging changes before and after therapy, clear ultra-low frequency transcranial magnetic stimulation for sleep disorder Parkinson's disease treatment, to explore the mechanism of action, compare the difference between different modes.
Studieoversigt
Status
Ukendt
Intervention / Behandling
Detaljeret beskrivelse
Parkinson's disease is the second most common chronic neurodegenerative disease.At present, researchers focus not only on the motor symptoms of Parkinson's disease, but also on the non-motor symptoms of Parkinson's disease (including mood disorders, sleep disorders, cognitive decline, and autonomic nervous kinetic disorder, etc.).The principle of transcranial magnetic stimulation is based on the electromagnetic principle proposed by Faraday.
When an electrifying coil is suspended over the scalp at a certain distance, the magnetic field generated by the coil current and the electric field generated by the magnetic field can reach the skull and directly or indirectly affect the synapses and neurons in the brain.The study by giving a sleep disorder Parkinson's disease patients with different patterns of ultra-low frequency transcranial magnetic stimulation or sham stimulation, scale for assessment of the patients were observed, hematology and imaging changes before and after therapy, clear ultra-low frequency transcranial magnetic stimulation for sleep disorder Parkinson's disease treatment, to explore the mechanism of action, compare the difference between different modes.
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
99
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Shandong
-
Jinan, Shandong, Kina
- The First Affiliated Hospital of Shandong First Medical University
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 70 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- in line with international Movement disorders association (the Movement Disorder Society, MDS) in 2015 the diagnosis of Parkinson's disease diagnosis standard and China standard (2016)
- can cooperate to complete rating scale, the sleep monitoring, imaging and blood test
- have a sleep disorder
- aged 18 to 70 years old
- agree to participate in this experiment, and have signed the informed consent
Exclusion Criteria:
- superposition of diagnosed with Parkinson's syndrome
- secondary diagnosed Parkinson's syndrome
- is equipped with heart pacemakers and other metal implants
- cannot achieve scale assessment
- has significant malignant diseases
- has a history of seizures
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: 5-HT mode of Ultra-low frequency repetitive transcranial magnetic stimulation
The study used 5-HT mode of Ultra-low frequency repetitive transcranial magnetic stimulation for 35 minutes once a day.Every 7 days is a cycle.The stimulus intensity was 400GS.
|
Two different modes of the instrument were used to treat patients in groups, to compare the efficacy.
|
|
Aktiv komparator: GABA mode of ultra-low frequency repetitive transcranial magnetic stimulation
The study used GABA mode of ultra-low frequency repetitive transcranial magnetic stimulation for 35 minutes once a day.Every 7 days is a cycle.The stimulus intensity was 400GS
|
Two different modes of the instrument were used to treat patients in groups, to compare the efficacy.
|
|
Sham-komparator: the control group
The instrument is not working, only in exhaust mode.
|
Two different modes of the instrument were used to treat patients in groups, to compare the efficacy.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
change from length of sleep at one week
Tidsramme: one week
|
Sleep duration was monitored by polysomnography.It's measured in minutes.
|
one week
|
|
change from ratio of stage 3 sleep in total sleep at one week
Tidsramme: one week
|
The proportion of phase 3 sleep in total sleep was monitored by polysomnography.It's in percentages.
|
one week
|
|
change from limb movement of sleep at one week
Tidsramme: one week
|
The number of body movements during sleep was recorded by polysomnography.It's in units of times per night.
|
one week
|
|
change from nocturnal arousal frequency at one week
Tidsramme: one week
|
The number of nocturnal awakenings was recorded by polysomnography.It's in units of times per night.
|
one week
|
|
change from Pittsburgh sleep quality index scale at one week
Tidsramme: 1 day before treatment、1 day after treatment、1 week after treatment、1 moth after treatment
|
The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranges from 0 to 2L, and the higher the score, the worse the sleep quality.
|
1 day before treatment、1 day after treatment、1 week after treatment、1 moth after treatment
|
|
Interleukin 6
Tidsramme: 1 day before treatment and 1 day after treatment
|
It plays an important role in central nervous system diseases.
In PD, the increase of IL-6 is the body's self-defense mechanism to protect neurons, and the change of IL-6 in peripheral blood can reflect the change of injury aggravation and recovery.It is also associated with psychiatric symptoms, and IL-6 is elevated in major depression.
|
1 day before treatment and 1 day after treatment
|
|
change from the Epworth sleepiness scale at one week
Tidsramme: one week
|
The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The scale has an overall score range of 0 to 24, with higher scores indicating more severe sleepiness.
|
one week
|
|
change from Parkinson's disease sleep scale at one week
Tidsramme: one week
|
The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranges from 0 to 150.
The higher the score, the better the sleep.
|
one week
|
|
change from movement disorders association - comprehensive rating scale of Parkinson's disease at one week
Tidsramme: one week
|
The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranged from 0 to 260, and the higher the score, the more severe the symptoms were.
|
one week
|
|
change from Parkinson's disease quality of life scale one week
Tidsramme: one week
|
The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranges from 0 to 156, and the higher the score, the worse the quality of life.
|
one week
|
|
change from Hamilton depression scale at one week
Tidsramme: one week
|
The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranged from 0 to 96, and the higher the score, the more severe the depression was.
|
one week
|
|
change from Hamilton anxiety scale at one week
Tidsramme: one week
|
The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranges from 0 to 56, and the higher the score, the more serious the anxiety.
|
one week
|
|
change from simple mental state scale at one week
Tidsramme: one week
|
The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranges from 0 to 30, and the lower the score, the more severe the cognitive impairment.
|
one week
|
|
change from Montreal cognitive assessment scale at one week
Tidsramme: one week
|
The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranges from 0 to 30, and the lower the score, the more severe the cognitive impairment.
|
one week
|
|
change from magnetic resonance imaging of the brain at one month
Tidsramme: one month
|
The ADC values of sleep-related brain tissues were measured by diffusion weighted magnetic resonance imaging of the brain.Compare the difference between the measured results on both sides of the same site and record the difference.
|
one month
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Xiuhua Li, MD, Qianfoshan Hospital,The First Affiliated Hospital of Shandong First Medical University
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
20. december 2019
Primær færdiggørelse (Forventet)
20. december 2021
Studieafslutning (Forventet)
20. april 2022
Datoer for studieregistrering
Først indsendt
8. marts 2021
Først indsendt, der opfyldte QC-kriterier
15. marts 2021
Først opslået (Faktiske)
18. marts 2021
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
24. marts 2021
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
20. marts 2021
Sidst verificeret
1. marts 2021
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Psykiske lidelser
- Patologiske processer
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Neurologiske manifestationer
- Parkinsonlidelser
- Basal Ganglia Sygdomme
- Bevægelsesforstyrrelser
- Synukleinopatier
- Neurodegenerative sygdomme
- Sygdom
- Parkinsons sygdom
- Søvnvågningsforstyrrelser
- Parasomnier
Andre undersøgelses-id-numre
- ULFRTMS-S
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
produkt fremstillet i og eksporteret fra U.S.A.
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Parkinsons sygdom
-
University of LahoreAfsluttet
-
Abbott Medical DevicesBaylor College of Medicine; University of HoustonAfsluttet
-
Bial - Portela C S.A.Afsluttet
-
CND Life SciencesDigestive Disease Associates of CTRekrutteringParkinsons sygdom | Parkinson | PARKINSON SYGGE (lidelse) | Parkinsons sygdomForenede Stater
-
iRegene Therapeutics Co., Ltd.RekrutteringEn fase I/III klinisk undersøgelse til evaluering af NouvNeu001-injektion til multippel systematrofiMultipel systematrofi - Parkinson subtype (MSA-P)Kina
-
Danish Research Centre for Magnetic ResonanceUniversity Hospital Bispebjerg and FrederiksbergRekrutteringSund og rask | Parkinson | Administration af medicinDanmark
-
Mayo ClinicAfsluttet
-
Bezmialem Vakif UniversityRekrutteringParkinsons sygdom | Parkinson | Parkinsons sygdom (PD) | PARKINSON SYGGE (lidelse) | Parkinsons sygdomTyrkiet (Türkiye)
-
CND Life SciencesOregon Health and Science UniversityRekrutteringParkinsons sygdom | Parkinson | Parkinsons sygdom og Parkinsonisme | PARKINSON SYGGE (lidelse)Forenede Stater
-
AstraZenecaParexelRekrutteringAvancerede solide tumorerSpanien, Forenede Stater, Sydkorea, Det Forenede Kongerige
Kliniske forsøg med Ultra-low frequency repetitive transcranial magnetic stimulation
-
Shirley Ryan AbilityLabAfsluttetAldersrelateret hukommelsessvækkelseForenede Stater
-
Peking University Sixth HospitalRekrutteringTardiv dyskinesi | Gentagen transkraniel magnetisk stimuleringKina
-
Central South UniversityIkke rekrutterer endnuSkizofreni | Maniodepressiv | Major Depressive Disorder (MDD)Kina
-
Tianjin Huanhu HospitalRekrutteringParkinsons sygdom | Kognitiv svækkelseKina
-
Mclean HospitalStanley Medical Research InstituteAfsluttetDepression | Maniodepressiv | Bipolar depressionForenede Stater
-
Ain Shams UniversityAfsluttetCerebral lille karsygdom | Balance | Gangforstyrrelser | Gentagen transkraniel magnetisk stimulering (rTMS)Egypten
-
Weill Medical College of Cornell UniversityAfsluttetBehandlingsresistent depressionForenede Stater
-
Shalvata Mental Health CenterUkendtBorderline personlighedsforstyrrelseIsrael
-
Stanford UniversityVA Palo Alto Health Care SystemRekrutteringTranskraniel magnetisk stimulering | MetamfetaminbrugsforstyrrelseForenede Stater
-
Shalvata Mental Health CenterUkendtTvangslidelse | Tourettes syndromIsrael